|Bid||325.43 x 1000|
|Ask||334.50 x 800|
|Day's range||325.82 - 331.78|
|52-week range||243.17 - 354.46|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||26.53|
|Earnings date||02 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||371.19|
Wall Street thinks this stock will rise 12% over the next 12 months. Let's first address why some on Wall Street don't have greater expectations for Vertex. One of the biggest factors is the biotech stock's previous success.
The good news is that if you've got the money and the time, it's not all that hard to find great investment options. If the company hits the high end of that range and its share price grows to reflect that internal growth, an initial investment of $10,000 would increase in value to over $163,000 in two decades. The company's infrastructure assets include natural gas pipelines, electricity transmission lines, smart meters, rail operations, toll roads, telecom towers, data centers, and semiconductor manufacturing foundries.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Warren Buffett thinks that near-term economic and market forecasts are "worse than useless." My hunch is that the U.S. economy is headed for a mild recession. Like most investors who aren't billionaires with the surname Buffett, I don't like to see the stocks I buy go down.
A few successful drugs are all that are required for a biotech company to shine. Vertex Pharmaceuticals (NASDAQ: VRTX) is well-known for its star product, Trikafta, a cystic fibrosis (CF) medicine. In the most recent first quarter, Trikafta contributed nearly $2.1 billion of the $2.3 billion in total product revenue.
Gene-editing healthcare therapies and renewable energy are two of the strongest trends today and for the next few years. Both sectors are worthy of sizable investments, particularly if you're looking to make long-term investments. CRISPR (clustered regularly interspaced short palindromic repeats) gene editing was discovered in 2012, and has the potential to revolutionize some aspects of health care.
CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.
Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was hard on most stocks, this year seems to be going pretty well for these two growth stocks.
Shares of Facebook's and Instagram's parent company, Meta Platforms (NASDAQ: META), tanked last year in response to top-line revenue that contracted for the first time since the company went public in 2012. In the fourth quarter of 2022, the company's operating margin shrank to 20%, which did not compare well to the 40% operating margin the company reported in 2021. To right the ship, Meta CEO Mark Zuckerberg announced sweeping layoffs earlier this year and declared 2023 would be a much-needed year of efficiency.
Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade.
Last year, the stock market went into a downward spiral, and growth stocks as a group were dragged down more than most. This year, the stock market appears to be recovering. Before their likely rebounds make them too expensive, here are two growth stocks to consider investing in now.
A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share. As of Tuesday afternoon, the biotech stock was at $64. While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet.
The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Among the best performers within the growth stock landscape this week were biopharmaceuticals.
It's always a great idea to buy stocks and hold them for the long term. That means at least five years. This offers you the opportunity to benefit from any dividend payments and/or growth in earnings.
Vertex Pharmaceuticals (NASDAQ: VRTX) is already a rock star in the world of cystic fibrosis (CF) treatment. The company's drugs have been life-changing for children and adults living with the disease. It's also helped the company build up more than $11 billion in cash to support development of new CF drugs and candidates in other areas.
Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise.
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today.
CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.
Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.
Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.
Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Deere & Company (DE) and Marsh & McLennan Companies, Inc. (MMC).
Stag Industrial (NYSE: STAG) and Vertex Pharmaceuticals (NASDAQ: VRTX) are off to a good start this year, and some industry tailwinds look to really boost shares in the coming years. Vertex, already a leader in cystic fibrosis treatment, is on the tip of a gene-editing revolution. Stag is a real estate investment trust (REIT) that specializes in renting out single-tenant industrial properties with triple-net leases.
BOSTON, May 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages 1 month to less than four months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO® based on clinical and/or in vitro assay data. KALYDECO® is already approved in the U.S. and EU for the treatment
Had you bought Vertex Pharmaceuticals (NASDAQ: VRTX) shares 10 years ago, you'd be sitting pretty right now. The drugmaker soundly outperformed the market over that period thanks to its success in developing medicines that target cystic fibrosis. The first of Vertex's products to treat that rare genetic disease was approved in 2012.